文献リスト

1) Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004; 351: 1521-31

2) Ikeda K, Arase Y, Kobayashi M, et al. Hepatitis B virus-related hepatocellular carcinogenesis and its prevention. Intervirology. 2005; 48: 29-38

3) Tsuboi Y, Ohkoshi S, Yano M, et al. Common clinicopathological features of the patients with chronic hepatitis B virus infection who developed hepatocellular carcinoma after seroconversion to anti-HBs─ a consideration of the pathogenesis of HBV-induced hepatocellular carcinoma and a strategy to inhibit it. Hepatogastroenterology. 2006; 53: 110-4

4) Sun HC, Tang ZY, Wang L, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006; 132: 458-65

5) Someya T, Ikeda K, Saitoh S, et al. Interferon loweres tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis. J Gastroenterol. 2006; 41: 1206-13

6) Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol. 2007; 46: 45-52

7) Ikeda K, Arase Y, Saitoh S, et al. Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts. J Hepatol. 2006; 44: 1089-97

8) Yoshizawa H, Tanaka J, Miyakawa Y. National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population. Intervirology. 2006; 49: 7-17

9) Soga K, Shibasaki K, Aoyagi Y. Effect of interferon on incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Hepatogastroenterology. 2005; 52: 1154-8

10) Moriyama M, Matsumura H, Aoki H, et al. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransaminase levels became less than twice the upper limit of normal following interferon therapy. Liver Int. 2005; 25: 85-90

11) Akuta N, Suzuki F, Suzuki Y, et al. Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival. Scand J Gastroenterol. 2005; 40: 688-96

12) Saito Y, Saito H, Tada S, et al. Effect of long-term interferon therapy for refractory chronic hepatitis C: preventive effect on hepatocarcinogenesis. Hepatogastroenterology. 2005; 52: 1491-6

13) Nishikawa M, Nishiguchi S, Kioka K, et al. Interferon reduces somatic mutation of mitochondrial DNA in liver tissues from chronic viral hepatitis patients. J Viral Hepat. 2005; 12: 494-8

14) Hung CH, Lee CM, Lu SN, et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat. 2006; 13: 409-14

15) Damdinsuren B, Nagano H, Wada H, et al. Stronger growth-inhibitory effect of interferon (IFN)-beta compared to IFN-alpha is mediated by IFN signaling pathway in hepatocellular carcinoma cells. Int J Oncol. 2007; 30: 201-8

16) Yano H, Ogasawara S, Momosaki S, et al. Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006; 26: 964-75

17) Murashima S, Tanaka M, Haramaki M, et al. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. Dig Dis Sci. 2006; 51: 808-12

18) Sakaguchi Y, Kudo M, Fukunaga T, et al. Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology. 2005; 48: 64-70

19) Hung CH, Lee CM, Wang JH, et al. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol. 2005; 20: 1553-9

20) Nishiguchi S, Tamori A, Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology. 2005; 48: 71-5

21) Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006; 44: 1543-54

22) Ikeda K, Arase Y, Kobayashi M, et al. A long-term glycyrrhizin therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients. Dig Dis Sci. 2006; 51: 603-9

23) Veldt BJ, Hansen BE, Ikeda K, et al. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Scand J Gastroenterol. 2006; 41: 1087-94

24) Rino Y, Tarao K, Morinaga S, et al. Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis. Anticancer Res. 2006; 26: 2221-6

25) Arrieta O, Rodriguez-Diaz JL, Rosas-Camargo V, et al. Colchichine delays the development of hepatocellular carcinoma in patients with hepatitis virus-erelated liver cirrhosis. Cancer. 2006; 107: 1852-8

26) Inoue M, Yoshimi I, Sobue T, et al. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst. 2005; 97: 293-300

27) Tanaka K, Hara M, Sakamoto T, et al. Inverse association between coffee drinking and the risk of hepatocellular carcinoma: a case-control study in Japan. Cancer Sci. 2007; 98: 214-8

28) Kurosawa Y, Ogimoto I, Shibata A, et al. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer. 2005; 93: 607-10

29) Montella M, Polesel J, LaVecchia C, et al. Coffee and tea consumption and risk of hepatocellular carcinoma in Italy. Int J Cancer. 2007; 120: 1555-9

30) El-Nezami HS, Polychronaki NN, Ma J, et al. Probiotic supplementation reduces a biomarker for increased risk of liver cancer in young men from Southern China. Am J Clin Nutr. 2006; 83: 1199-203

31) Takai K, Okuno M, Yasuda I, et al. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. Updated analysis of the long-term follow-up data. Intervirology. 2005; 48: 39-45

32) Sano T, Kagawa M, Okuno M, et al. Prevention of rat hepatocarcinogenesis by acyclic retinoid is accompanied by reduction in emergence of both TGF-alpha-expressing oval-like cells and activated hepatic stellate cells. Nutr Cancer. 2005; 51: 197-206

33) Kuriyama S, Hitomi M, Yoshiji H, et al. Vitamins K2, K3 and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules. Int J Oncol. 2005; 27: 505-11

34) Yoshiji H, Kuriyama S, Noguchi R, et al. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindoril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J Hepatol. 2005; 42: 687-93

35) Sakakima Y, Hayakawa A, Nagasaka T, et al. Prevention of hepatocarcinogenesis with phosphatidylcholine and menaquinone-4: In vitro and in vivo experiments. J Hepatol. 2007; 27: 83-92

36) Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006; 66: 11851-8

37) Ma L, Luo L, Qiao H, et al. Complete eradication of hepatocellular cacinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J Hepatol. 2007; 46: 98-106

38) Torimura T, Ueno T, Kin M, et al. Gene transfer of kringle 1-5 supresses tumor development and improves prognosis of mice with hepatocellular carcinoma. Gastroenterology. 2006; 130: 1301-10

39) Zhao QT, Yue SQ, Cui Z, et al. Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis. Life Sci. 2007; 80: 484-92

40) Liu W, Nakamura H, Tsujimura T, et al. Chemoprevention of spontaneous development of hepatocellular carcinomas in fatty liver Shiionogi mice by a cyclooxigenase-2 inhibitor. Cancer Sci. 2006; 97: 768-73

41) Dombrowski F, Flaschka C, Klotz L, et al. Hepatocellular neoplasmas after intrahepatic transplantation of ovarian fragments into ovariectomized rats. Hepatology. 2006; 43: 857-67

42) Di Bisceglie AM, Osmack P, Brunt EM. Chemoprevention of hepatocellular carcinoma: use of tamoxifen in an animal model of hepatocarcinogenesis. J Lab Clin Med. 2005; 145: 134-8

43) Schiffer E, Housset C, Cacheux W, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with chrrhosis. Hepatology. 2005; 41: 307-14

44) Taras D, Blanc JF, Rullier A, et al. Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. J Hepatol. 2007; 46: 69-76

45) Ohira M, Ohdan H, Mitsuta H, et al. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy. Transplantation. 2006; 27: 1712-9

46) Hasegawa K, Takayama T, Ijichi M, et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology. 2006; 44: 891-5

47) Li Q, Wang J, Sun Y, et al. Postoperative transhepatic arterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma: a randomized study with 131 cases. Dig Surg. 2006; 23: 235-40

48) Togo S, Tanaka K, Masui H, et al. Usefulness of prophylactic transcatheter arterial infusion of anticancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection. Int Surg. 2005; 90: 103-8

49) Tabone M, Vigano'L, Ferrero A, et al. Prevention of intrahepatic recurrence by adjuvant (131)iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis. Eur J Surg Oncol. 2007; 33: 61-6

50) Bernal E, Montero JL, Delgado M, et al. Adjuvant chemotherapy for prevention of recurrence of invasive hepatocellular carcinoma after orthotopic liver transplantation. Transplant Proc. 2006; 38: 2495-8

51) Ogawa T, Tashiro H, Miyata Y, et al. Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. Am J Transplant. 2007; 7: 347-55

52) Xu J, Shen ZY, Chen XG, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplantation. Hepatology. 2007; 45: 269-7

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp